Spitzer on Plan B
This article was originally published in The Tan Sheet
Executive Summary
New York Attorney General Eliot Spitzer "will sign into law" a bill that would allow for pharmacy access to Barr Labs' emergency contraceptive Plan B if he is elected as the state's governor later this year, Spitzer stated in a recent speech. His campaign for women's health rights has earned him the endorsement of the pro-choice advocacy groups NARAL and Planned Parenthood. Current Gov. George Pataki (R) vetoed pharmacy access legislation in August after it was passed by the state legislature (1"The Tan Sheet" Aug. 8, 2005, In Brief). "This bill should not have been vetoed," Spitzer states. "We need to pass that bill again." Separately, Barr Pharmaceuticals will be added to the S&P 500 index effective Feb. 24, according to a Feb. 21 announcement. Barr will replace Scientific-Atlanta, which is being acquired by Cisco Systems...
You may also be interested in...
Pataki vetoes OTC Plan B
New York Gov. George Pataki (R) vetoed a bill that would have provided OTC access without parental consent to the emergency contraceptive Plan B (levonorgestrel .75 mg) Aug. 4. The "Unintended Pregnancy Prevention Act" (S 3661) passed the state Senate June 22. Pataki cited lack of protection for minors in his decision and voiced concerns that the bill "lacks several other safeguards." The Family Planning Advocates of New York State called the governor's decision "tragic." Pataki's decision follows Massachusetts Gov. Mitt Romney's (R) July 25 veto of a similar measure...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.